Program on Thursday, 16 February 2017

Scientific Congress Schedule

Download Online Program
Search

Legend:
Plenary
State of the Art
NEW, HOT or DISCUSSED
Symposium
Highlight
Working Group
Oral Communication
Workshop
Poster
Miscellaneous
Sat./Lunch Symposium
  • Chairs:


    F. Langer (Hamburg, Germany)
    B. Zieger (Freiburg, Germany)
  • 8:00
    Von Willebrand factor processing
    Journal article „Hämostaseologie“

    M. A. Brehm (Hamburg, Germany)

  • 8:25
    Acquired Von Willebrand syndrome in patients with aortic valve disease

    S. Susen (Lille Cedex, France)

  • 8:50
    Effect of DDAVP on hemostasis - more than just VWF release

    L. Alberio (Lausanne, Switzerland)

  • Chairs:


    K. Jurk (Mainz, Germany)
    J. Koscielny (Berlin, Germany)
  • 8:00
    Indications and triggers for platelet transfusions

    B. Mansouri Taleghani (Bern, Switzerland)

  • 8:25
    In vitro platelet production

    D. Baruch (Paris, France)

  • 8:50
    Platelet proteomics

    R. Zahedi (Dortmund, Germany)

  • Chairs:


    H.-P. Kohler (Bern, Switzerland)
    L. Muszbek (Debrecen, Hungary)
  • 8:00
    Novel biochemical and structural aspects of FXIII

    L. Muszbek (Debrecen, Hungary)

  • 8:25
    FXIII and fibrin structure

    R. Ariëns (Leeds, United Kingdom)

  • 8:50
    FXIII-A in energy metabolism

    M. Kaartinen (Montreal, Canada)

  • Chairs:


    L. Graf (St. Gallen, Switzerland)
    M. Spannagl (Munich, Germany)
  • 8:00
  • 8:12
    Diagnosing heparin-induced thrombocytopenia (HIT) in 30 minutes : A prospective evaluation of a rapid diagnostic work-up.

    M. Marchetti, S. Barelli, F. Monnin, N. Nicolas, E. Matthey, C. Gerschheimer, L. Alberio (Lausanne, Switzerland)

  • 8:24
    Multianalyte determination of NOAC using LC-MS/MS and comparison with functional coagulation assays

    L. Slavik, J. Lukes, M. Zhanelova, M. Nemcova, J. Ulehlova, J. Prochazkova, A. Hlusi, M. Palova, J. Vaclavik (Olomouc, Czech Republic)

  • 8:36
  • 8:48
    Spatial fibrin clot formation is less affected by clotting factor deficiency than thrombin generation

    E. Zöhrer, A. Schlagenhauf, S. Pohl, B. Leschnik, H. Haidl, S. Gallistl (Graz, Austria)

  • 9:00
    Catching microparticles - a methodical comparison

    C. Plattfaut, F. Gieseler, A. Freund, G. Riemekasten, A. Müller (1Lübeck, Germany)

  • Chairs:


    R. Bauersachs (Darmstadt, Germany)
    S. Konstantinides (Mainz, Germany)
  • 8:00
    Predictive variables of recurrence - how to choose long-term anticoagulation in VTE

    P. A. Kyrle (Vienna, Austria)

  • 8:25
    Advantages and limitations of patient self-management of oral anticoagulation in VKA

    W. A. Wuillemin (Luzern, Switzerland)

  • 8:50
    Post-thrombotic syndrome - implications and management

    A. ten Cate-Hoek (Maastricht, The Netherlands)

  • Chairs:


    K. Kurnik (Munich, Germany)
    N. von der Weid (Basel, Switzerland)
  • 8:00
    Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate
    Journal article „Hämostaseologie“

    E. Berntorp (Malmö, Sweden)

  • 8:25
    Gynecological aspects of adolescents with rare bleeding disorders

    R. Kulkarni (East Lansing, United States)

  • 8:50
    Care, needs and perceptions of adolescents and young adults growing up with hemophilia A or B in Germany

    D. Richter, C. Heller, M. Heuer, S. Schultze-Strasser, D. Schwabe, C. Königs (Frankfurt am Main, Germany)

  • 9:02
    An alternative immune tolerance induction therapy for patients with inhibitors in hemophilia A

    W.-A. Hassenpflug, J. Schrum, R. Dittmer, R. Schneppenheim (Hamburg, Germany)

  • Chairs:


    M. A. Brehm (Hamburg, Germany)
    E. R. Weibel (Bern, Switzerland)
  • 9:30
    Life cycle of Weibel Palade bodies
    Journal article „Hämostaseologie“

    H. J. Eikenboom (Leiden, The Netherlands)

  • 10:00
    Regulation of angiogenesis by Von Willebrand factor

    A. Randi (London, United Kingdom)

  • Announcement and Presentation of Awardee

    Bayer Science and Education Foundation
    B. Kemkes-Matthes (Giessen, Germany)

  • Chairs:


    A. Ichinose (Yamagata, Japan)
    V. Schröder (Bern, Switzerland)
  • 10:45
    Functional and clinical aspects of FXIII

    H.-P. Kohler (Bern, Switzerland)

  • 11:10
    The first case of congenital FXIII deficiency - A Swiss story

    V. Schröder (Bern, Switzerland)

  • 11:35
    Acquired FXIII deficiency

    A. Ichinose (Yamagata, Japan)

  • 12:00
    Coagulation factor XIII: its possible role in corneal wound healing

    Z. Z. Orosz1,2, A. Szöor1, Z. Veréb2, Z. Hassan1, E. Katona1, G. Vereb1, A. Facskó2, L. Muszbek1 (1Debrecen, Hungary, 2Szeged, Hungary)

  • Chairs:


    B. Kehrel (Muenster, Germany)
    M. Skowronska (Bern, Switzerland)
  • 11:00
    New treatment options for thrombotic thrombocytopenic purpura (TTP)

    P. Knöbl (Vienna, Austria)

  • 11:20
    Clinical Pearl

    B. Kemkes-Matthes (Giessen, Germany)

  • 11:35
    Warfarin inhibits VKORC1 by competitive slow tight binding

    K. J. Czogalla1, A. Biswas1, K. Höning1, V. Hornung1,2, K. Liphardt1, M. Watzka1, J. Oldenburg1 (1Bonn, Germany, 2Munich, Germany)

  • 11:47
    Cardiac Protease-Activated Receptor 2 expression is involved in cardiac fibrosis, diastolic dysfunction and immunological response in the aged heart

    J. Friebel1, M. Witkowski1, A. Weithäuser1, K. Savvatis2, D. Steffens1, M. Kasner1, T. Tabaraie1, M. Wegner1, U. Landmesser1, U. Rauch-Kröhnert1 (1Berlin, Germany, 2London, United Kingdom)

  • Chairs:


    M. Schaller Tschan (Bern, Switzerland)
    W. A. Wuillemin (Luzern, Switzerland)
  • 11:00
    Differential effects of novel anticoagulants: FXa versus FIIa inhibition on coagulation and inflammation

    S. Nazir1, K. Shahzad1, I. Gadi1, M. Al-Dabet1, S. Kohli1, S. Ranjan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)

  • 11:06
    Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca2+ signaling

    S. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (1Tübingen, Germany)

  • 11:12
    P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in mice

    J. Merz, P. Stachon, P. Albrecht, F. Ünal, S. von Garlen, A. Heidenreich, N. Hoppe, B. Duffner, C. Bode, A. Zirlik (Freiburg, Deutschland)

  • 11:18
    Introduction of a guideline for the treatment of synovitis in patients with hemophilia

    B. Habermann1, A. Seuser2, T. Hilberg3 (1Mainz, Germany, 2Bonn, Germany, 3Wuppertal, Germany)

  • 11:24
  • 11:30
    CLIC1 supports mechanisms related to thrombosis and vascular repair

    L. M. Knowles, P. Niewald, E. Ampofo, A. Drawz, I. Müller, H. Eichler, J. Pilch (Homburg, Germany)

  • 11:36
    Collagen V alpha 2 as a direct target of miR-143 in arteriogenesis

    T. Hammerschick1, K. Troidl2, K. T. Preissner1, S. Fischer1 (1Giessen, Germany, 2Bad Nauheim, Germany)

  • 11:42
    Phosphorylation of the protein phosphatase 2A inhibitor alpha-endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human platelets

    E. Walter1, O. Pagel2, R. Zahedi2, A. Smolenski3, S. Gambaryan1,4, U. Walter1, K. Jurk1 (1Mainz, Germany, 2Dortmund, Germany, 3Dublin, Ireland, 4St. Petersburg, Russia)

  • 11:48
  • 11:54
    FSAP and altered fibrin clot structure: Is there a link to FXIII?

    M. Etscheid, N. Beer, R. Seitz, J. Dodt (Langen, Germany)

  • Chairs:


    W. Miesbach (Frankfurt am Main, Germany)
    D. Tsakiris (Basel, Switzerland)
  • 11:00
    A new era of treatment for patients with hemophilia A with and without inhibitors?

    R. Klamroth (Berlin, Germany)

  • 11:15
    Clinical Pearl

    J.-D. Studt (Zurich, Switzerland)

  • 11:30
  • 11:47
    Targeting anticoagulant protein S to achieve hemostasis in hemophilia

    S. Calzavarini1, L. Bologna1, R. Prince1, M. Manetti2, D. Melchiorre2, I. Rosa2, N. Dewarrat1, P. Amini1, J.A. Fernandez3, C. Quarroz1, Y. Matsumura4, J.A. Kremer Hovinga1, J.H. Griffin3, H-U. Simon1, L. Ibba Maneschi2, F. Saller5, A. Angelillo-Scherrer1 (1Bern, Switzerland, 2Florence, Italy, 3La Jolla, USA, 4Chiba, Japan, 5Paris, France)

  • Chairs:


    L. Asmis (Zurich, Switzerland)
    I. Pabinger-Fasching (Vienna, Austria)
  • 11:00
    Highlight Thrombosis

    R. E. Scharf (Duesseldorf, Germany)

  • 11:20
    Clinical Pearl

    C. Ay (Vienna, Austria)

  • 11:35
    Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a large multicenter cohort study

    F. Dentali1, S. Pegoraro1, S. Barco2, M. di Minno2, D. Mastroiacovo3, F. Pomero4, C. Lodigiani5, F. Bagna6, W. Ageno1, M. di Nisio7 (1Varese, Italy, 2Mainz, Germany, 3Naples, Italy, 4Avezzano, Italy, 5Cuneo, Italy, 6Rozzano-Milano, Italy, 7Chieti, Italy)

  • 11:47
    Platelet transcriptome analysis of mice with altered thrombin signaling

    S. Schubert, F. Marini, C. Santos, H. Binder, W. Ruf (Mainz, Germany)

  • Chairs:


    A. Huth-Kühne (Heidelberg, Germany)
    J. A. Kremer Hovinga (Bern, Switzerland)
  • 12:15
    Voncento®: Studiendaten und klinische Anwendung

    C. Bidlingmaier (Munich, Germany)

  • 12:38
    Angeborene Thrombozytopathien und Differentialdiagnose

    B. Zieger (Freiburg, Germany)

  • 13:00
    Facetten des VWS: Angiodysplasien

    W. Eberl (Braunschweig, Germany)

  • 13:22
    Faktor IX - ein faszinierendes Molekül

    J. A. Kremer Hovinga (Bern, Switzerland)

  • Chairs:


    B. Kemkes-Matthes (Giessen, Germany)
    W. Korte (St. Gallen, Switzerland)
  • 12:15
    Begrüssung

    W. Korte (St. Gallen, Switzerland)

  • 12:20
    Venöse Thromboembolien - Studienlage und Realität zu Behandlungskonzepten und Therapieansätzen

    S. Haas (Munich, Germany)

  • 12:40
    NOAKs im Alltag - Gibt es noch Überraschungen?

    J. Beyer-Westendorf (Dresden, Germany)

  • 12:55
    Diskussion
  • 13:00
    Triple-Therapie mit NOAK - Praxis und Studienlage

    C. Bode (Freiburg, Germany)

  • 13:20
    Praktisches Management in besonderen Situationen - Do's and Dont's

    W. A. Wuillemin (Luzern, Switzerland)

  • 13:40
    Diskussion
  • 13:40
    Zusammenfassung

    B. Kemkes-Matthes (Giessen, Germany)

  • Chairs:


    I. Hegemann (Zurich, Switzerland)
    K. Schmitt (Linz, Austria)
  • 12:15
    Inhibitor development in haemophilia A - A lifelong challenge

    C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)

  • 12:35
    How to start treatment in hemophilia A PUPs in the light of the SIPPET study - single center experience

    S. Halimeh (Duisburg, Germany)

  • 13:00
    Management of surgeries in VWD - maintaining the balance

    L. Graf (St. Gallen, Switzerland)

  • 13:20
    Current aspects of prohylaxis in VWD

    U. Nowak-Göttl (Kiel, Germany)

  • Chairs:


    D. Tsakiris (Basel, Switzerland)
    N. von der Weid (Basel, Switzerland)
  • 12:15
    Introduction

    D. Tsakiris (Basel, Switzerland)
    N. von der Weid (Basel, Switzerland)

  • 12:20
    Features of recombinant Factor Fc - Immunological potential

    F. Nimmerjahn (Erlangen, Germany)

  • 12:40
    Elocta & Alprolix - Long term data in adults and adolescents

    R. Klamroth (Berlin, Germany)

  • 13:00
    Elocta & Alprolix - Long term data in children

    C. Wermes (Hanover, Germany)

  • 13:20
    How to use Elocta - Real world experience from Bonn

    G. Goldmann (Bonn, Germany)

  • 13:40
    Conclusion & Discussion

    D. Tsakiris (Basel, Switzerland)
    N. von der Weid (Basel, Switzerland)
    F. Nimmerjahn (Erlangen, Germany)
    R. Klamroth (Berlin, Germany)
    G. Goldmann (Bonn, Germany)
    C. Wermes (Hanover, Germany)

  • Chairs:


    C. Königs (Frankfurt am Main, Germany)
    J. Oldenburg (Bonn, Germany)
    J. Rischewski (Luzern, Switzerland)
  • 12:15
    Neue Konzepte in der Hämophiliebehandlung - Grundlagen der Gentherapie

    T. van den Driessche (Brussels, Belgium)

  • 12:45
    Fallstricke der Faktorenmessung im Hämostase-Labor

    U. Scholz (Leipzig, Germany)

  • 13:15
    Haemoassist 2 - eine gute Prognose

    A. Tiede (Hanover, Germany)

  • Chairs:


    Z. Cermakova (Ostrava, Czech Republic)
    R. Rieben (Bern, Switzerland)
  • 14:00
    Microvascular flow model to study clot formation in real-time

    L. Jenny1, J. Dobó2, P. Gál2, W. Lam3, V. Schroeder1 (1Bern, Switzerland, 2Budapest, Hungary, 3Atlanta, Unites States)

  • 14:12
    rhADAMTS13 treatment improves ventricular remodeling and functionality after cardiac injury in mice

    T. Witsch1,2, K. Martinod2, D. D. Wagner2 (1Freiburg, Germany, 2Boston, USA)

  • 14:24
  • 14:36
    In vitro evaluation of aptamer-based reversible inhibition of anticoagulant activated protein C as a novel supportive hemostatic approach

    N. Shahidi Hamedani1, H. Rühl1, S. Gasper1, J. J. Zimmermann1, T. Heiseler2, J. Oldenburg1, G. Mayer1, B. Pötzsch1, J. Müller1 (1Bonn, Germany, 2Dreieich, Germany)

  • 14:48
  • 15:00
    Interim results from a dose escalating study of AMT-060 (AAV5-hFIX) gene transfer in adult patients with severe haemophilia B

    W. Miesbach8, M. Tangelder1, K. Meijer2, G. Castaman3, F. Cattaneo4, M. Coppens1, P. Kampmann5, R. Klamroth6, R. Schutgens7, E. Seifried8, J. Schwaeble8, (1Amsterdam, The Netherlands, 2Groningen, The Netherlands, 3Florence, Italy, 4Parma, Italy, 5Copenhagen, Denmark, 6Berlin, Germany, 7Utrecht, The Netherlands, 8Frankfurt, Germany)

  • Chairs:


    Y. Fujimura (Nara, Japan)
    B. Lämmle (Mainz, Germany)
  • 14:00
    Management of pregnancy in carriers of hemophilia and rare bleeding disorders

    U. Scholz (Leipzig, Germany)

  • 14:25
    Insights into preeclampsia and HELLP

    M. Mohaupt (Bern, Switzerland)

  • 14:50
    Pregnancy in patients with acquired and hereditary TTP

    A. S. von Krogh (Trondheim, Norway)

  • Chairs:


    T. Bakchoul (Tuebingen, Germany)
    C.-E. Dempfle (Mannheim-Lindenhof, Germany)
  • 14:00
    Role of platelet factor 4 (PF4) and anti-PF4/polyanion IgG in human platelet FcγRIIA mediated anti-bacterial activity

    R. Palankar, T. Kohler, N. Medvedev, J. Wesche, K. Krauel, S. Hammerschmidt, A. Greinacher (Greifswald, Germany)

  • 14:12
    Platelet activation and aggregation provoked by Staphylococcus aureus secreted proteins

    U. Binsker1, J. Wesche1, R. Palankar1, T. P. Kohler1, J. Prucha1, B. Bröker1, U. Mamat2, J. Pané-Farré1, F. Schmidt1, A. Greinacher1, S. Hammerschmidt1 (1Greifswald, Germany, 2Borstel, Germany)

  • 14:24
    Altered platelet lipidomic profile influences thrombotic disposition: modulation by the CXCL12-CXCR4-CXCR7 Axis

    M. Chatterjee, D. Rath, J. Schlotterbeck, J. Rheinlaender, B. Walker-Allgaier, T. E. Schäffer, M. Lämmerhofer, M. Gawaz (1Tübingen, Germany)

  • 14:36
    Metformin alters the epigenetic regulation of tissue factor in diabetes

    M. Witkowski1, A. Weithauser1, T. Tabaraie1, D. Steffens1, J. Friebel1, A. Doerner1, M. Kasner1, B. Stratmann2, D. Tschoepe2, U. Landmesser1, U. Rauch1 (1Berlin, Germany, 2Bad Oeyenhausen, Germany)

  • 14:48
    D-Dimer, but not the Khorana score predicts venous thromboembolism in lung cancer patients

    E. Grilz, O. Königsbrügge, J. Riedl, J. Thaler, R. Pirker, C. Ay, I. Pabinger (Vienna, Austria)

  • 15:00
    Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks

    B. Giannetti1, V. Grivcheva Panovska2, D. Moldovan3, A. Reshef4, S. Andrejevic5, R. Hakl6, S. Kivity7, L. Bellizzi1, A. Relan1, B. Giannetti1, M. Cicardi8 (1Leiden, The Netherlands, 2Skopje, Republic of Macedonia, 3Tirgu Mures, Romania, 4Tel-Hashomer, Israel, 5Belgrade, Serbia, 6Brno, Czech Republic, 7Tel Aviv, Israel, 8Milan, Italy)

  • Chairs:


    G. Auerswald (Bremen, Germany)
    C. Königs (Frankfurt am Main, Germany)
  • 14:00
    Role and mode of action of T cells in inhibitor formation in hemophilia A

    K. Pratt (Bethesda, United States)

  • 14:25
    Immune tolerance treatment in children and in adults with hemophilia and inhibitors

    R. d'Oiron (Le Kremlin-Bicêtre, France)

  • 14:50
    Insights into the autoimmune response in acquired hemophilia A

    A. Tiede (Hanover, Germany)

  • Chairs:


    V. Hach-Wunderle (Frankfurt am Main, Germany)
    M. Schindewolf (Bern, Switzerland)
  • 14:00
    How to prevent chronic thromboembolic pulmonary hypertension after PE/VTE

    S. Konstantinides (Mainz, Germany)

  • 14:25
    Minimal-invasive endovascular treatment of acute deep vein thrombosis

    N. Kucher (Bern, Switzerland)

  • 14:50
    Surgical and interventional therapy for chronic thromboembolic pulmonary hypertension (CTEPH)

    C. B. Wiedenroth (Bad Nauheim, Germany)

  • Chairs:


    P. A. Kyrle (Vienna, Austria)
    E. Lindhoff-Last (Frankfurt am Main, Germany)
  • 15:30
    Fibrinogen, factor XIII, and red blood cells in thrombosis
    Journal article „Hämostaseologie“

    A. S. Wolberg (Chapel Hill, United States)

  • 16:00
    Thrombophilia and pregnancy complications

    S. Middeldorp (Amsterdam, The Netherlands)

  • Chairs:


    J. Koscielny (Berlin, Germany)
    W. Miesbach (Frankfurt am Main, Germany)
  • 16:45
    Begrüssung und Einführung

    J. Koscielny (Berlin, Germany)
    W. Miesbach (Frankfurt am Main, Germany)

  • 16:50
    Individuelle Behandlung atypischer VWD-Patienten

    C.-E. Dempfle (Mannheim-Lindenhof, Germany)

  • 17:10
    Diskussion
  • 17:15
    Von Willebrand-Faktor bei Patienten in der Herzchirurgie

    U. Scholz (Leipzig, Germany)

  • 17:35
    Diskussion
  • 17:40
    Prevention of hemorrhage after implantation of mechanical circulatory support

    S. Susen (Lille Cedex, France)

  • 18:00
    Diskussion
  • 18:05
    Zusammenfassung

    J. Koscielny (Berlin, Germany)
    W. Miesbach (Frankfurt am Main, Germany)

  • Chairs:


    H. Riess (Berlin, Germany)
  • 16:45
    VTE-Prophylaxe im klinischen Alltag - Hochrisikopatienten und perioperatives Management im Fokus

    C. von Heymann (Berlin, Germany)

  • 17:15
    Update 2017: Was gibt es Neues in der Behandlung tumorassoziierter Thromboembolien?

    H. Riess (Berlin, Germany)

  • 17:45
    German Evaluation of Cancer Associated Thrombosis (GECAT) - Eine prospektive Registerstudie zur Versorgung onkologischer Patienten mit VTE

    R. Klamroth (Berlin, Germany)

  • Chairs:


    G. Auerswald (Bremen, Germany)
    J. A. Kremer Hovinga (Bern, Switzerland)
  • 16:45
    Bedeutung der individualisierten Physiotherapie aus der Sicht des Hämostaseologen, Orthopäden und Physiotherapeuten. Ein Expertendialog

    S. Halimeh (Duisburg, Germany)
    M. Rosenthal (Duisburg, Germany)
    A. Seuser (Bonn, Germany)

  • 17:25
    GuardianTM9: Untersuchung der Pharmakokinetik von Turoctocog alfa im Verhältnis zum BMI

    G. Goldmann (Bonn, Germany)

  • 17:45
    Individual pharmacokinetic assessment - the WAPPS-Hemo Project

    A. McEneny-King (Waterloo, Canada)

  • Chairs:


    D. Tsakiris (Basel, Switzerland)
  • 16:45
    Monitoring der Heparine: APTT, Thrombinzeit oder Anti-FXa?

    W. A. Wuillemin (Luzern, Switzerland)

  • 17:05
    Diskussion
  • 17:15
    Monitoring der DOAC: Wann, wie, bei wem?

    D. Peetz (Berlin, Germany)

  • 17:35
    Diskussion
  • 17:45
    Thrombophilie-Screening und Interferenzen durch die DOAC

    S. Eichinger-Hasenauer (Vienna, Austria)

  • 18:05
    Diskussion, Zusammenfassung und Schlussbemerkungen
  • Chairs:


    A. Huth-Kühne (Heidelberg, Germany)
  • 16:45
    Begrüssung und Einleitung

    A. Huth-Kühne (Heidelberg, Germany)

  • 16:55
    Die Evolution der Hämophilie A Behandlung

    F. Langer (Hamburg, Germany)

  • 17:25
    Der pädiatrische EHL-Patient – alles gleich oder doch ganz anders?

    C. Bidlingmaier (Munich, Germany)

  • 17:50
    Wer EHL sagt, muss auch PK sagen

    I. Hegemann (Zurich, Switzerland)

keyboard_arrow_up